Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rationale for a Neisseria gonorrhoeae Susceptible–only Interpretive Breakpoint for Azithromycin

4 Apr 2019

Abstract excerpt

BACKGROUND: Azithromycin (AZI) is recommended with ceftriaxone (CRO) for treatment of uncomplicated gonococcal urethritis and cervicitis in the United States, and an AZI-susceptibility breakpoint is needed. Neither the Food and Drug Administration (FDA) nor the Clinical and Laboratory Standards Institute (CLSI) has set interpretive breakpoints for AZI susceptibility. As a result, AZI antimicrobial susceptibility...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Neonatal and Maternal Infections
Share to Reproductive tract infections research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30963175
DOI: 10.1093/cid/ciz292

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rationale for a Neisseria gonorrhoeae Susceptible–only Interpretive Breakpoint for AzithromycinPMID 30963175Read ↗

Analysis of Neisseria gonorrhoeae Azithromycin Susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013Semantic proximity Read ↗

Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance dataSemantic proximity Read ↗

[Unveiling Neisseria gonorrhoeae Survival: Genetic Variability, Pathogenesis, and Antimicrobial Drug Resistance].Semantic proximity Read ↗

<em>Neisseria gonorrhoeae</em> in the Era of Antimicrobial Resistance: From Curable STI to Clinical ChallengeSemantic proximity Read ↗

Molecular Diagnostics for Gonorrhoea: Implications for Antimicrobial Resistance and the Threat of Untreatable GonorrhoeaSemantic proximity Read ↗

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.Semantic proximity Read ↗

Genomic Epidemiology of Azithromycin-Nonsusceptible Neisseria gonorrhoeae, Argentina, 2005–2019Semantic proximity Read ↗

Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century.Semantic proximity Read ↗

Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae.Semantic proximity Read ↗

Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance studySemantic proximity Read ↗

Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018Semantic proximity Read ↗

Genomic Characterization of Neisseria gonorrhoeae Strains from 2016 U.S. Sentinel Surveillance Displaying Reduced Susceptibility to Azithromycin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.